Vinflunine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Vinflunine
Accession Number
DB11641
Type
Small Molecule
Groups
Approved
Description

Vinflunine is an ingredient in the EMA-authorised product Javlor.

Structure
Thumb
Synonyms
Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
JavlorInjection, solution, concentrate25 mg/mlIntravenousPierre Fabre Médicament2009-09-21Not applicableEu
JavlorInjection, solution, concentrate25 mg/mlIntravenousPierre Fabre Médicament2009-09-21Not applicableEu
JavlorInjection, solution, concentrate25 mg/mlIntravenousPierre Fabre Médicament2009-09-21Not applicableEu
JavlorInjection, solution, concentrate25 mg/mlIntravenousPierre Fabre Médicament2009-09-21Not applicableEu
JavlorInjection, solution, concentrate25 mg/mlIntravenousPierre Fabre Médicament2009-09-21Not applicableEu
JavlorInjection, solution, concentrate25 mg/mlIntravenousPierre Fabre Médicament2009-09-21Not applicableEu
JavlorInjection, solution, concentrate25 mg/mlIntravenousPierre Fabre Médicament2009-09-21Not applicableEu
JavlorInjection, solution, concentrate25 mg/mlIntravenousPierre Fabre Médicament2009-09-21Not applicableEu
JavlorInjection, solution, concentrate25 mg/mlIntravenousPierre Fabre Médicament2009-09-21Not applicableEu
JavlorInjection, solution, concentrate25 mg/mlIntravenousPierre Fabre Médicament2009-09-21Not applicableEu
Categories
UNII
5BF646324K
CAS number
162652-95-1
Weight
Average: 816.944
Monoisotopic: 816.390971041
Chemical Formula
C45H54F2N4O8
InChI Key
NMDYYWFGPIMTKO-KLCPSUAYSA-N
InChI
InChI=1S/C45H54F2N4O8/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3/t26-,27+,36-,37+,38+,42+,43+,44-,45-/m0/s1
IUPAC Name
methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-4-[(1R,12S,14S,16R)-16-(1,1-difluoroethyl)-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0^{3,11}.0^{4,9}]octadeca-3(11),4,6,8-tetraen-12-yl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2,4,6,13-tetraene-10-carboxylate
SMILES
CC[[email protected]@]12C=CCN3CC[[email protected]@]4([[email protected]]13)[[email protected]@H](N(C)C1=CC(OC)=C(C=C41)[[email protected]]1(C[[email protected]@H]3C[[email protected]](C[[email protected]@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[[email protected]](O)([[email protected]@H]2OC(C)=O)C(=O)OC

Pharmacology

Indication
Not Available
Structured Indications
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Vinflunine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Vinflunine.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Vinflunine.Approved, Investigational, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Vinflunine.Approved, Investigational
CarbomycinThe serum concentration of Vinflunine can be increased when it is combined with Carbomycin.Vet Approved
ClarithromycinThe serum concentration of Vinflunine can be increased when it is combined with Clarithromycin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Vinflunine.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Vinflunine.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Vinflunine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Vinflunine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Vinflunine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vinflunine.Approved
ErythromycinThe serum concentration of Vinflunine can be increased when it is combined with Erythromycin.Approved, Vet Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Vinflunine.Experimental
JosamycinThe serum concentration of Vinflunine can be increased when it is combined with Josamycin.Approved, Investigational
KitasamycinThe serum concentration of Vinflunine can be increased when it is combined with Kitasamycin.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Vinflunine.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Vinflunine.Experimental
MitomycinThe risk or severity of adverse effects can be increased when Vinflunine is combined with Mitomycin.Approved
OleandomycinThe serum concentration of Vinflunine can be increased when it is combined with Oleandomycin.Vet Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Vinflunine.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Vinflunine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Vinflunine.Experimental
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vinflunine.Approved, Investigational, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Vinflunine.Experimental
SolithromycinThe serum concentration of Vinflunine can be increased when it is combined with Solithromycin.Investigational
SpiramycinThe serum concentration of Vinflunine can be increased when it is combined with Spiramycin.Approved
TelithromycinThe serum concentration of Vinflunine can be increased when it is combined with Telithromycin.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Vinflunine.Approved, Investigational
TylosinThe serum concentration of Vinflunine can be increased when it is combined with Tylosin.Vet Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Vinflunine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
8804619
ChEBI
90241
ChEMBL
CHEMBL2110725
ATC Codes
L01CA05 — Vinflunine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentBladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureteral Cancer / Urethral Cancer1
1CompletedTreatmentCancers2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentCancers1
1, 2CompletedTreatmentAdvanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy1
1, 2Not Yet RecruitingTreatmentBladder Cancers1
2Active Not RecruitingTreatmentLocally-advanced or Metastatic Penile Neoplasms1
2CompletedTreatmentBladder Cancers / Neoplasm, Bladder / Neoplasms, Kidney / Transitional Cell Carcinoma / Ureter Neoplasms1
2CompletedTreatmentBladder Transitional Cell Carcinoma Stage IV1
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCarcinoma, Small Cell / Lung Cancers1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentTransitional Cell Carcinoma1
2RecruitingTreatmentBladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureteral Cancer / Urethral Cancer1
2TerminatedTreatmentLung Cancers1
2WithdrawnTreatmentCancer, Breast1
2, 3CompletedTreatmentBladder Cancers / Metastasis / Transitional Cell Carcinoma1
2, 3TerminatedTreatmentMalignant Neoplasm of Stomach1
2, 3Unknown StatusTreatmentUrothelium Transitional Cell Carcinoma1
3Active Not RecruitingTreatmentBladder Cancers1
3Active Not RecruitingTreatmentRecurrent or Metastatic Head and Neck Carcinoma1
3Active Not RecruitingTreatmentUrothelial Cancer1
3CompletedTreatmentBladder Cancers / Neoplasm, Bladder / Transitional Cell Carcinoma of the Urothelial Tract1
3CompletedTreatmentCancer, Breast / Metastases1
3CompletedTreatmentMalignant Neoplasm of Breast1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solution, concentrateIntravenous25 mg/ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00564 mg/mLALOGPS
logP4.5ALOGPS
logP4.65ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)10.87ChemAxon
pKa (Strongest Basic)8.66ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area133.87 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity216.53 m3·mol-1ChemAxon
Polarizability85.68 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as vinca alkaloids. These are alkaloids with a dimeric chemical structure composed of an indole nucleus (catharanthine), and a dihydroindole nucleus (vindoline), joined together.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Vinca alkaloids
Sub Class
Not Available
Direct Parent
Vinca alkaloids
Alternative Parents
Ibogan-type alkaloids / Carbazoles / 3-alkylindoles / Tricarboxylic acids and derivatives / Dialkylarylamines / Anisoles / Aralkylamines / Alkyl aryl ethers / Piperidines / N-alkylpyrrolidines
show 14 more
Substituents
Vinca alkaloid skeleton / Catharanthine skeleton / Carbazole / 3-alkylindole / Indole / Indole or derivatives / Tricarboxylic acid or derivatives / Anisole / Dialkylarylamine / Tertiary aliphatic/aromatic amine
show 34 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 17, 2016 15:30 / Updated on December 08, 2017 12:23